Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
NCT ID: NCT04638426
Last Updated: 2020-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
196 participants
INTERVENTIONAL
2020-09-10
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A
HL237 tab. 200mg/day
HL237 tablet
Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Treatment B
HL237 tab. 400mg/day
HL237 tablet
Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Treatment C
HL237 tab. 800mg/day
HL237 tablet
Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Placebo
Placebo of HL237 tab.
Placebo of HL237 tablet
Placebo of HL237, twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HL237 tablet
Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Placebo of HL237 tablet
Placebo of HL237, twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In the case of women of childbearing age, those who have a negative pregnancy test before randomization
* Patients who agree to use a medically accepted method of contraception during the clinical trial
* Patients corresponding to ACR functional class Ⅰ,Ⅱ,Ⅲ
* Patients with active rheumatoid arthritis with DAS28-ESR \> 3.2 in the evaluation of DAS28-ESR identified at the screening
* Patients who were diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria at least 3 months prior to the screening, and showed insufficient response or refractory to treatment with one or more DMARDs.
* Among the subjects who have previously been continuously administering the following rheumatoid arthritis drugs without stopping, those who have used them according to the conditions before randomization and can maintain the current administration regimen and dose during the clinical trial.
* cDMARDs : Patients who received the same cDMARDs for 12 weeks or more continuously and did not change the dosage and administration of the cDMARDs for 4 weeks or more until the 2nd visit(ex. methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, bucillamine etc.)
* Prednisolone : Patients who received corticosteroids with a daily dose of 10mg or less of oral prednisolone equivalent continuously, and did not change the dosage and administration for more than 2 weeks until the 2nd visit.
* Tramadol or NSAIDs : Patients who did not change the dosage and administration for more than 2 weeks consecutively until the 2nd visit
* Patients who have completed the wash-out period as follows until the 2nd visit including the screening period (each period refers to the case where it continues consecutively, and these drugs are contraindicated from the screening).
* bDMARDs abatacept, adalimumab, certolizumab pegol, golimumab : 10 weeks or more anakinra : 10 days or more etanercept : 3 weeks or more infliximab : 8 weeks or more tocilizumab : 5 weeks or more rituximab : 6 months or more
* JAK inhibitors tofacitinib, baricitinib : 2 weeks or more
* immunosuppressants tacrolimus, cyclosporin, azathioprine, cyclophosphamide mizoribine etc : 4 weeks or more
* tramadol, analgesics and anti-inflammatory analgesic other than NSAIDs : 4 days or more
* Volunteer, be willing and able to provide written informed consent for the trial
* Patients who can read and understand written instructions
Exclusion Criteria
* Patients with acquired immune deficiency syndrome or autoimmune diseases other than rheumatoid arthritis
* Severe heart failure, congestive heart failure (NYHA II～IV), ischemic heart disease, peripheral artery disease and/or cerebrovascular disease
* Patients with a history of gastrointestinal bleeding or perforation due to treatment of nonsteroidal anti-inflammatory drugs
* Patients with bleeding or a current history of blood coagulation disorder
* Patients suffering from infectious disease (including tuberculosis, shingles, etc.) at the time of screening or undergoing treatment with the medical history
* Patients with a history of malignant tumors within 5 years prior to screening
* Patients with peptic ulcer confirmed by endoscopy or radiographic examination within 6 months prior to screening
* Patients with a history of gastric or duodenal perforation or obstruction, patients with a history of gastrointestinal surgery (except appendicitis), and patients with a history of upper or lower gastrointestinal bleeding (excluding simple hemorrhoids) within the past year
* Patients with symptoms or signs of pyloric obstruction
* Patients diagnosed with malabsorption within 12 weeks prior to the screening
* Patients with hypersensitive reaction or history of clinically significant hypersensitive reaction to investigational product or its excipients
* Patients with aspirin asthma (asthma attacks caused by nonsteroidal anti-inflammatory drugs) or a history of the same
* Patients with inflammatory bowel disease such as crohn's disease or ulcerative colitis
* Pregnant or breast-feeding
* Patients administered intraarticular, intramuscular, intravenous corticosteroids within 4 weeks priro to the screening.
* Patients with significant psychiatric disorders or taking antidepressants, anticonvulsants, or sedatives
* Patients with substance or alcohol abuse or dependence
* Patients who participate in other clinical trials within 12 weeks prior to the screening and administer investigational drugs or apply clinical trial medical devices
* Patients expected to inevitably administer contraindicated drugs during the clinical trial
* Patients with severe renal dysfuntion(seurum creatinine is 2.0 times higher than the upper limit of normal (based on the institution))
* Patients with severe liver dysfuntion(ALT, AST or total bilirubin is 2.0 times higher than the upper limit of normal (based on the institution))
* Patients that the investigator deems unsuitable for participation in the clinical trial
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanlim Pharm. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea Seoul ST.MARY'S Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HL237-201
Identifier Type: -
Identifier Source: org_study_id